论文部分内容阅读
作者应用干扰素(IF)治疗慢性非甲非乙型肝炎(NANBH),通过以肝功能改善为指标作长期及短期疗效观察对比研究;还以新发现的丙型肝炎病毒(HCV)抗体的变化作治疗效果观察。慢性NANBH的诊断标准:①肝功能异常持续1年以上,肝活检示慢性肝炎表现;②HBsAg及HBV-DNA阴性;③抗核抗体、抗平滑肌抗体及抗线粒体抗体均阴性;④有输血或应用兴奋剂史;⑤除酒精或病毒性原因外,无明显肝病原因者。16例中,长期组为投药1年,观察1年者,短期组为投药7～13周,各8例。长、短期组之年龄分别为48±9.3和48±6.6岁,性别(男/女)分别为6/2和5/3;均有输液或用药不当史。谷丙转氨酶分别为210±50和217±199;慢性持续性肝炎/慢性活动性肝炎/肝硬化为2/5/1;抗-HCV阳性分别为6/8和5/8。应用α型IF肌注,0.3～9.0MU/次,一周3次。总药量:长期组140～468(平均340)MU,
The authors used interferon (IF) in the treatment of chronic non-A, non-B hepatitis (NANBH), comparing the long-term and short-term effects of liver function improvement as an indicator; also with the newly found hepatitis C virus (HCV) antibody changes For the treatment effect observation. Chronic NANBH diagnostic criteria: ① abnormal liver function over 1 year, liver biopsy showed chronic hepatitis; ② HBsAg and HBV-DNA negative; ③ anti-nuclear antibodies, anti-smooth muscle antibodies and anti-mitochondrial antibodies were negative; ④ blood transfusion or application of excitement Agent history; ⑤ except alcohol or viral reasons, no obvious cause of liver disease. In 16 cases, the long-term group was administered for 1 year, observed for 1 year, short-term group for 7 to 13 weeks, each 8 cases. The age of the long-term and short-term groups were 48 ± 9.3 and 48 ± 6.6 years, respectively, and the sex (male / female) was 6/2 and 5/3, respectively; both had improper infusion or medication history. Alanine aminotransferase were 210 ± 50 and 217 ± 199 respectively; chronic persistent hepatitis / chronic active hepatitis / cirrhosis was 2/5/1; anti-HCV positive were 6/8 and 5/8, respectively. Application of α-IF intramuscular injection, 0.3 ~ 9.0MU / time, three times a week. Total dose: Long-term group 140 ~ 468 (average 340) MU,